Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...

For the 80 million people worldwide with celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. But researchers are hoping to change that with a new ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

As the flu season ramps up, a mutated A(H3N2) strain is already driving outbreaks in Canada, the UK, and Japan. That’s why ...

Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study. PD-1 blockade in combination with bevacizumab and nab-paclitaxel for second-line treatment in ...

Lipid nanoparticle (LNP) mRNA vaccines induce robust immune responses and provide protection against infectious diseases. However, this immunity can be short-lived, resulting in the need for frequent ...

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma. Treatment with cemacabtagene ansegedleucel (cema-cel) ...